Valeant CEO Timothy Tyson and President, North America Wesley Wheeler: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
Valeant execs outline development plans for taribavirin for hepatitis C, licensing opportunities and goals for ramping up the commercial organization ahead of potential new launches.
You may also be interested in...
Valeant Seeking Return To Growth With New Chief Executive
Valeant names J. Michael Pearson, who with McKinsey & Co. assisted in reorganization, firm tells “The Pink Sheet” DAILY.
Valeant Seeking Return To Growth With New Chief Executive
Valeant names J. Michael Pearson, who with McKinsey & Co. assisted in reorganization, firm tells “The Pink Sheet” DAILY.
Valeant CEO Timothy Tyson and President, North America Wesley Wheeler: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Execs provide an update on plans for recharging Cesamet following a sluggish launch, and development plans for a new potential entry: retigabine for seizures.